A Study to Assess Adverse Events and Change in Disease Activity of HArmonyCa Lidocaine Injectable Gel for Mid Face Soft Tissue Augmentation in Adult Participants

PHASE3CompletedINTERVENTIONAL
Enrollment

171

Participants

Timeline

Start Date

September 2, 2022

Primary Completion Date

May 8, 2025

Study Completion Date

May 8, 2025

Conditions
Mid Face Volume Deficit
Interventions
DEVICE

HArmonyCa Lidocaine Injectable Gel

Subdermal or deep dermal injection

Trial Locations (12)

29016

Instituto Medico Miramar /ID# 240939, Málaga

V5Z 1H2

YVR Aesthetics Training & Study Centre /ID# 239809, Vancouver

V5Z 4E1

Humphrey & Beleznay Cosmetic Dermatology /ID# 239805, Vancouver

V6H 4E1

Pacific Derm /ID# 240785, Vancouver

V6M 4J2

Skin Matters Medical Aesthetic Centre /ID# 239986, Vancouver

L7N 3N2

Dermetics Cosmetic Dermatology /ID# 246536, Burlington

L6J 7W5

The Centre for Clinical Trials /ID# 246409, Oakville

L4L 8E2

Bertucci MedSpa Inc. /ID# 246496, Woodbridge

H3C 1Z3

Erevna Innovations Inc. /ID# 240401, Westmount

08006

WM Hospitals /ID# 245747, Barcelona

EH3 6RS

Dr Nestor's Medical Cosmetic Centre /ID# 246406, Edinburgh

B74 2UG

MediZen /ID# 240102, Sutton Coldfield

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Allergan

INDUSTRY